secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-197047
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 discontinues EBO-301 MAC lung study, cuts ~50% workforce, shifts pipeline focus
--------------------------------------------------------------------------------

- Phase 2/3 EBO-301 study discontinued; sputum culture conversion at Month 6: 13.2% vs 10.0% (p=0.64).
- Reduction in force of ~50% of employees; expects $2-3M in severance charges.
- CMO Paul Eckburg departs Aug 30, 2024; will continue as consultant with vesting.
- Company shifts focus to boron chemistry platform; plans Phase 1 for Chagas, Phase 2 for melioidosis.
- Cost savings expected to extend cash runway through 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/0001193125-24-197047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524197047/d865374d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-197047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer